Alzheimer’s Early Detection Act of 2026

This bill would require group health plans, private health insurers, and state Medicaid programs to cover Alzheimer's biomarker testing, which analyzes blood, tissue, or other samples to detect, diagnose, treat, or monitor Alzheimer's disease. Plans could not set cost-sharing or treatment limits for this testing that are stricter than those for most other medical benefits, and could not require step therapy first. If a plan requires prior approval, it must decide within 72 hours (24 hours in urgent cases), or the request is treated as approved. The requirements would start one year after the bill becomes law, and the National Institutes of Health would report to Congress yearly for three years on the value of this testing.

Full text and official record on Congress.gov

Sponsors

• Jake Auchincloss Democrat sponsor
• 2 cosponsors